Objective To investigate the relationship between serum soluble Fas/soluble FasL and antiviral effi-cacy in patients with chronic hepatitis C (CHC). Methods A total of 40 cases of CHC patients, who were admitted to our hospital and cooperative units from January 2014 to January 2015, was selected as the case group, and 20 cases of healthy cases of voluntary blood donors were enrolled as a control group. The serum levels of soluble Fas and soluble FasL before treatment, 4 weeks and 24 weeks after treatment in two groups were determined and compared. According to the results of HCV RNA, the case group was further divided into two subgroups (RVR group and nRVR group) for analysis. Results The serum soluble Fas and soluble FasL levels before treatment in case group [(17.67 ± 2.90)μg/L, (0.165 ± 0.013)μg/L, respectively] were significantly higher than control group [(7.87 ± 1.24)μg/L, (0.098 ± 0.007)μg/L, respectively) (P<0.05). After 4 weeks of treatment, the serum levels of soluble Fas and soluble FasL in RVR group [(11.56 ± 2.82)μg/L, (0.109 ± 0.010)μg/L, respectively] were significantly lower than nRVR group [(16.93 ± 2.56)μg/L, (0.161±0.017)μg/L, respectively] (P<0.05). Moreover, the serum soluble Fas and soluble FasL levels in case group were significantly higher than control group (P<0.05). After 24 weeks of treatment, the serum soluble Fas and soluble FasL levels in RVR group [(8.95 ± 1.49)μg/L, (0.099 ± 0.008)μg/L, respectively] were significantly lower than nRVR group [(12.07±2.45)μg/L, (0.145+0.014)μg/L, respectively] (P<0.05), while there was no statistical significance difference be-tween case group and control group (P>0.05). Conclusion After 24 weeks of treatment, the levels of serum soluble Fas and soluble gradually decreased to normal in patients with chronic hepatitis C, so the serum levels of soluble Fas and sol-uble FasL can be used to predict therapeutic effect of patients with chronic hepatitis C.%目的 探讨血清可溶性Fas、FasL与慢性丙型肝炎(CHC)患者抗病毒疗效的关系.方法 选择2014年1月至2015年1月期间在我院及协作单位就诊的40例CHC患者作为病例组,另选20例在我院及协作单位无偿献血的健康者作为对照组.病例组患者于治疗前、治疗4周、24周时测定血清可溶性Fas、FasL水平,健康组于病例组患者治疗前同期测定上述参数,比较两组的差异;并根据丙型肝炎病毒核糖核酸(HCV RNA)是否转阴将病例组分为两个亚组(RVR组和nRVR组),进行比较分析.结果 治疗前病例组患者的血清可溶性Fas、FasL水平分别为(17.67±2.90)μg/L、(0.165±0.013)μg/L,明显高于对照组的(7.87±1.24)μg/L、(0.098±0.007)μg/L,差异均有统计学意义(P<0.05);治疗4周后,RVR组患者的血清可溶性Fas、FasL分别为(11.56±2.82)μg/L、(0.109±0.010)μg/L,明显低于nRVR组的(16.93±2.56)μg/L、(0.161±0.017)μg/L,差异均有统计学意义(P<0.05),且病例组血清可溶性Fas、FasL高于对照组,差异具有统计学意义(P<0.05);治疗结束后24周,RVR组患者的血清可溶性Fas、FasL水平分别为(8.95±1.49)μg/L、(0.099±0.008)μg/L,明显低于nRVR组的(12.07±2.45)μg/L、(0.145±0.014)μg/L,差异均有统计学意义(P<0.05),但病例组与对照组比较差异无统计学意义(P>0.05).结论 慢性丙型肝炎患者治疗后血清可溶性Fas、FasL含量降低,趋向于正常值,治疗后24周血清可溶性Fas、FasL接近正常值.因此,血清可溶性Fas、FasL水平可预测慢性丙型肝炎患者的治疗效果.
展开▼
